Bernard Jasmin (University of Ottawa) discusses the factors enabling the modification of myotonic dystrophy.
Caroline Le Guiner (Biotherapies Institute for Rare Diseases) discusses the development of products for gene therapy in Duchenne muscular dystrophy.
A summary of the third day at Myology 2016 in Lyon! Watch the testimonies of Nathalie Goemans (Hôpitaux Universitaires, Louvain), Aymeric Ravel-Chapuis (University of Ottawa), Géraldine Honnet (Biotherapies Institute for Rare Diseases) and Bernard Brais (McGill University, Québec).
Jerry Mendell told us about gene therapy in spinal muscular atrophy.
H. Lee Sweeney discusses the difficulty of having drugs approved for Duchenne Muscular Dystrophy.
Ichizo Nishino explains his successful results for Nonaka myopathy (GNE).
Wednesday opened on a symposium based on the development of innovative therapies, which make a new, booming type of medicine. Because the first drug candidates developed so far are only “prototypes”, researchers and doctors are building a strategy to tackle the disease on all fronts. Matthew Wood from Oxford University (UK) restored the expression of … [Read more]
Matthew Wood discusses the challenges of developing gene therapy
A summary of the second day at Myology 2016 in Lyon! Discover the testimonies of Denis Furling (Institute of Myology),Claire Legay (University Paris Descartes), Laurent Schaeffer (NeuroMyoGène Institute), Bénédicte Chazaud (NeuroMyoGène Institute), Jordan Mecca (Institute of Myology) and Pascal Maire (Cochin Institute).
Christophe Marcelle (University of Lyon, University of Melbourne) discusses muscle development.